Drug Profile
M 3541
Alternative Names: M3541Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Merck KGaA
- Developer EMD Serono Research & Development Institute; Merck KGaA
- Class Antineoplastics
- Mechanism of Action Ataxia telangiectasia mutated protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in USA (PO)
- 27 Apr 2020 Discontinued - Phase-I for Solid tumours (Combination therapy) in USA (PO) (NCT03225105)
- 27 Apr 2020 EMD Serono and Merck terminates a phase I trial in Solid tumours (Combination therapy) in USA (PO) due to sponsors decision (Due to pharmaceutical and PK/pharmacodynamic qualities that prevented continued clinical development of M 3541) (NCT03225105)